What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Daniel J. Sargent mainly focuses on Colorectal cancer, Internal medicine, Oncology, Surgery and Cancer.
His Colorectal cancer research is multidisciplinary, incorporating perspectives in Chemotherapy, Rectum, Microsatellite instability, Pathology and Adenocarcinoma.
His research investigates the connection between Pathology and topics such as Medical physics that intersect with problems in Unequivocal Progression, Rociletinib and Quality.
His research on Internal medicine often connects related topics like Gastroenterology.
His biological study spans a wide range of topics, including KRAS, Proportional hazards model and Adjuvant therapy.
His Surgery study combines topics from a wide range of disciplines, such as Neoadjuvant therapy and Predictive marker.
His most cited work include:
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) (14014 citations)
- A comparison of laparoscopically assisted and open colectomy for colon cancer. (2570 citations)
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer (1949 citations)
What are the main themes of his work throughout his whole career to date?
Daniel J. Sargent spends much of his time researching Internal medicine, Oncology, Colorectal cancer, Clinical trial and Surgery.
His work in Cancer, Oxaliplatin, Proportional hazards model, Fluorouracil and Chemotherapy is related to Internal medicine.
His work in Oncology covers topics such as DNA mismatch repair which are related to areas like Cancer research.
In his study, which falls under the umbrella issue of Colorectal cancer, Microsatellite instability is strongly linked to Pathology.
His work deals with themes such as Research design, Randomized controlled trial, Medical physics and Intensive care medicine, which intersect with Clinical trial.
His research on Surgery often connects related areas such as Adverse effect.
He most often published in these fields:
- Internal medicine (52.28%)
- Oncology (42.95%)
- Colorectal cancer (42.12%)
What were the highlights of his more recent work (between 2015-2020)?
- Internal medicine (52.28%)
- Oncology (42.95%)
- Colorectal cancer (42.12%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Colorectal cancer, Clinical trial and Randomized controlled trial.
His Oncology research integrates issues from Cancer, Adjuvant therapy, Oxaliplatin, Microsatellite instability and DNA mismatch repair.
His Colorectal cancer study which covers First line that intersects with Systemic chemotherapy.
His Clinical trial study combines topics in areas such as Progression-free survival, Intensive care medicine, Nomogram, Disease and Surrogate endpoint.
His Randomized controlled trial study is related to the wider topic of Surgery.
His research in Proportional hazards model intersects with topics in Young adult, Clinical endpoint and Performance status.
Between 2015 and 2020, his most popular works were:
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (665 citations)
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (301 citations)
- Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database (202 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Statistics
Daniel J. Sargent mostly deals with Colorectal cancer, Internal medicine, Oncology, Clinical trial and Proportional hazards model.
His Colorectal cancer research also works with subjects such as
- Pathology which is related to area like Intensive care medicine,
- Molecular biomarkers that intertwine with fields like Clinical Oncology.
His primary area of study in Internal medicine is in the field of Fluorouracil.
His Oncology research is multidisciplinary, incorporating elements of Cancer, Metastasis, Molecular diagnostics, FOLFOX and Hazard ratio.
His Clinical trial study incorporates themes from Predictive value of tests, Randomized controlled trial, Nomogram and Disease.
Daniel J. Sargent combines subjects such as Clinical endpoint and Performance status with his study of Proportional hazards model.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
